- Company
- K-Bio in ASCO 2020: Seeking the optimal combination
- by Choi sun May 27, 2020 06:07am
- From May 29, ten of Korean pharmaceutical and bio companies are to participate in the virtually held American Society of Clinical Oncology Annual Meeting (ASCO) 2020. GC Pharma, SillaJen, Genexine and many other Korean companies are planning to present various clinical study outcomes related to anticancer treatments. The ASCO annual
- Company
- KRPIA-MOHW meeting rescheduled on May 28
- by Eo, Yun-Ho May 27, 2020 06:05am
- Korean Research-based Pharmaceutical Industry Association (KRPIA) and Ministry of Health and Welfare (MOHW) have rescheduled their meeting canceled last week due to a confirmed case of COVID-19. According to a pharmaceutical industry source, a meeting between MOHW Pharmaceutical Benefits Division and KRPIA Market Access (MA) and Governme
- Opinion
- [Reporter’s view] We must prepare for the post impurity era
- by Kim, Jin-Gu May 27, 2020 06:04am
- The situation wasn't the worst. Unlike Ranitidine, not all Metformin sales have been stopped. It is expected that the confusion of patients and the potential damage of pharmaceutical companies will not be greater than in the case of the Valsartan·Ranitidine crisis. The MFDS decided to stop selling 31 of the 288 finished Metformin products
- Policy
- PVA lowers Entresto and Synovian pricing
- by Kim, Jung-Ju May 27, 2020 06:04am
- The prices of Novartis Korea’s Entresto film-coated tablet (sacubitril plus valsartan plus sodium salt hydrate complex) and LG Chem’s Synovian injection (BDDE bridged sodium hyaluronate gel) have been negotiated to be lowered by 7 percent and 2.7 percent, respectively, due to their increased use. Daewoong Pharmaceutical, Ildong Pharmaceuti
- Policy
- Benefit of COVID-19 medications completed in just one day
- by Lee, Hye-Kyung May 27, 2020 06:04am
- In order to prevent the spread of COVID-19 infection, the HIRA is the one which is drawing attention. The DUR system was used to help medical institutions check immigration visit information from around the world, and it shortened the review period for drug benefit standards that took more than 80 days on average to one day, promptly res
- Policy
- Ultomiris, a successor to Soliris, was approved in Korea
- by Lee, Tak-Sun May 27, 2020 06:04am
- Handok acquired a domestic item license for paroxysmal nocturnal hemoglobinuria (PNH) treatment 'Ultomiris'. Ultomiris is a product that was expected as a successor to Soliris, and is a drug developed by Alexion, like Soliris. In particular, it has attracted attention in that it has increased convenience by significantly reducing the numbe
- Policy
- Chloroquine was approved for export due to COVID-19
- by Lee, Tak-Sun May 26, 2020 06:06am
- iUnder the influence of COVID-19, the approval of Chloroquine for export used as a therapeutic agent has been followed. It seems that domestic pharmaceutical companies are targeting overseas exports and making items due to the worldwide pandemic phenomenon. According to the MFDS on the 25th, permission to Chloroquine and Hydroxychloroquine
- COVID-19 treatment guideline recommends hydroxychloroquine
- by Lee, in-bok May 26, 2020 06:06am
- Korean Association of Internal Medicine (KAIM) and its member academia have co-published a prescription guideline for treating patients with COVID-19. The guideline recommends hydroxychloroquine as the first preference, but does not recommend interferon or ribavirin monotherapy. The guideline also recommends Kaletra monotherapy, but it advise
- Policy
- Will Vyleesi known as Viagra for women be released?
- by Lee, Tak-Sun May 26, 2020 06:05am
- A product known as Viagra for Women conducts clinical trials in Korea. It is Vyleesi (Bremelanotide, injection type) introduced by Kwangdong Pharmaceutical. The MFDS approved a clinical trial phase III bridging study plan by Kwangdong Pharmaceutical on the 22nd. Bridging study is a test to prove whether new drugs developed in foreign count
- Company
- Prevenar13 by Pfizer sales increased 50%
- by An, Kyung-Jin May 26, 2020 06:05am
- Pfizer's pneumococcal vaccine 'Prevenar 13' had a high sales. It is evaluated that reflex profits appeared as anticipation for the effect of preventing pneumonia increased due to prolongation of COVID-19 outbreak. According to the drug research agency IQVIA on the 21st, 'Prevenar 13' sales in the first quarter increased 52.2% to &8361;17.
